Tislelizumab for older adults with advanced esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a drug called tislelizumab (an immunotherapy) in older adults (70+) with advanced esophageal cancer who cannot have standard chemotherapy. The goal is to see if the drug can slow or shrink the cancer safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of esophageal cancer called squamous cell carcinoma that has spread or is locally advanced.
- You are 70 years old or older and your doctors have decided you cannot have standard platinum chemotherapy.
- You have not had any treatment for this cancer before (like chemo, radiation, or immunotherapy).
- You have a tumor that can be measured on a scan, and you are generally feeling well enough to be up and about (WHO performance status 0-2).
- Your blood counts and organ function (kidney, liver) are good enough, as shown by recent lab tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and radiation, followed by surgery, for people with advanced esophageal cancer that cannot be removed right away. It aims to see if this approach can help shrink the tumor enough to allow surgery.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and radiation for older adults (70+) with advanced esophageal cancer that hasn't been treated before. The goal is to see if this approach can help control the cancer while keeping quality of life.
This trial tests whether combining tislelizumab (an immunotherapy drug) with chemotherapy can shrink advanced esophageal cancer before surgery. The goal is to help patients whose tumors are too large or invasive to operate on initially.
This study tests whether adding tislelizumab to chemotherapy or radiation can work better for older adults with advanced or recurrent/metastatic esophageal squamous cell cancer. The goal is to slow the cancer down and improve control of the disease.
This trial tests whether adding tislelizumab to chemoradiation as the first treatment helps people with advanced esophageal squamous cell cancer. It aims to improve how well the cancer responds when it cannot be cured with surgery or full-dose curative treatment.
This trial tests different schedules of tislelizumab (an immunotherapy drug) combined with chemotherapy for Japanese patients with advanced esophageal squamous cell carcinoma that cannot be removed by surgery or has spread. It aims to find a better way to give these treatments together.
Hear when a new Esophageal Squamous Cell Carcinoma (ESCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.